Table 3.

Clinical and molecular features of MMR-D colon cancer in relation to loss of MMR proteins.

Characteristic	No. of patients (%) with loss of:				P value	Pairwise P values
	MLH1/PMS2 (n = 137)	MSH2/6 (n = 18)	MSH6 alone (n = 5)	PMS2 alone (n = 4)
Age, yearsa	72 (28–89)	51 (25–91)	60 (47–73)	55 (38–70)	0.0003	0.002,b 0.130,c 0.130,d 0.587,e 0.902,f 0.667g
Sex
Female	79 (58)	7 (39)	1 (20)	2 (50)	0.191
Male	58 (42)	11 (61)	4 (80)	2 (50)	0.191
Stage
I/II	97 (71)	14 (78)	4 (80)	2 (50)	0.692
III	40 (29)	4 (22)	1 (20)	2 (50)
TIL level
High	99 (72)	13 (72)	1 (20)	2 (50)	0.066
Low	38 (28)	5 (28)	4 (80)	2 (50)
TMB, mt/Mba	53.5 (20.2–115)	71.6 (20.2–134.3)	70.2 (59.7–361.6)	87.8 (29–218.6)	0.001	0.003,b 0.083,c 0.324,d 0.941,e 0.807,f 0.876g
MSIsensor scorea	35 (10–52)	36.5 (10–48)	20 (18–29)	27 (17–43)	0.036	0.855,b 0.027,c 0.697,d 0.158,e 0.827,f 0.905g
No. of frameshiftsa
Deletions	15 (2–39)	19.5 (8–35)	5 (3–8)	8.5 (1–32)	0.001	0.313,b 0.002,c 0.313,d 0.003,e 0.313,f 0.902g
Insertions	4 (0–15)	4 (0–14)	2 (1–13)	12.5 (8–19)	0.010	0.543,b 0.382,c 0.011,d 0.514,e 0.012,f 0.130g

Abbreviations: MMR, mismatch repair; MSI-H, microsatellite instability-high; TIL, tumor-infiltrating lymphocytes; TMB, tumor mutational burden.

^aMedian (range)

^bMLH1/PMS2 vs MSH2/6

^cMLH1/PMS2 vs MSH6 alone

^dMLH1/PMS2 vs PMS2 alone

^eMSH2/6 vs MSH6 alone

^fMSH2/6 vs PMS2 alone

^gMSH6 only vs PMS2 alone